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Introduction. To enhance eﬀective treatment, african nations including Ghana changed its malaria treatment policy from
monotherapy to combination treatment with artesunate-amodiaquine (AS+AQ). The major challenge to its use in loose form
is adherence. Objective. The objectives of this study were to investigate adherence and treatment outcome among patients treated
with AS+AQ combination therapy for acute uncomplicated malaria. Methodology. The study was conducted in two rural districts
located in the middle belt of Ghana using quantitative methods. Patients diagnosed with acute uncomplicated malaria as per the
Ghana Ministry of Health malaria case deﬁnitions were randomly allocated to one of two groups. All patients in both groups
were educated about the dose regimen of AS+AQ therapy and the need for adherence. Treatment with AS+AQ was supervised
in one group while the other group was not supervised. Adherence was assessed by direct observation of the blister package
of AS+AQ left on day 2. Results. 401 participants were randomized into the supervised (211) and unsupervised (190) groups.
Compliance in both supervised (95.7%) and unsupervised (92.6%) groups were similar (P = .18). The commonest side-eﬀects
reported on day 2 among both groups were headaches, and body weakness. Parasite clearance by day 28 was >95% in both groups.
Discussion/Conclusions. Administration of AS-AQ in both groups resulted in high levels of adherence to treatment regimen among
adolescentandadultpopulationincentralGhana.ItappearsthathighlevelofadherencetoAS-AQisachievablethrougharigorous
education programme during routine clinic visits.
Copyright © 2009 Kwaku Poku Asante et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
It is estimated that about 2.7 million malaria deaths occur
annually with about 90% occurring in Africa [1]. Between
400 and 900 million cases of acute febrile episodes of
malaria occur yearly in children living in malaria endemic
regions [2]. Those children who do not die may suﬀer brain
damageorexperiencecognitiveandlearningdeﬁcits[3].The
most important drawback to successful control of malaria
is the development of resistance by Plasmodium species to
commonly-used anti-malarial drugs [4]. Artemisinin-based
combination therapy (ACT) has been demonstrated to
improve treatment eﬃcacy [5] and reduce the risk of drug
resistance and thus recommended by the World Health
Organisation as the ﬁrst line drug for treatment of malaria
[6]. Artesunate-amodiaquine (AS-AQ) combination therapy
has recently been introduced as the ﬁrst line drug of choice
for the treatment of uncomplicated P. falciparum malaria
in Ghana [7]. One of the main disadvantages of ACT is
achieving good adherence to treatment regimen [8]. In
Ghana,prepackagingofantimalarialshasbeendemonstrated
to improve adherence and therapeutic outcome [9–11].
However these studies evaluated chloroquine monotherapy
for treatment of malaria and not an ACT. It is envisaged2 Journal of Tropical Medicine
that adherence to artesunate-amodiquine (AS+AQ) therapy
would be faced with more challenges compared with chloro-
quine monotherapy because of the perceived side-eﬀects of
amodiaquine and limited access to ﬁxed dose combination
in the current market.
Adherence to ACTs could be enhanced by treatment
supervision by trained community workers. Supervisory
home visits by a trained community worker form a major
component of the Community Health Planning and Services
programme being implemented by the Ghana Health Service
[12].
This study assessed adherence to AS+AQ therapy and
alsotheeﬀectofadherencetoAS+AQtherapyonclinicaland
parasitological outcomes.
2.Methodology
2.1. Study Site. The study was carried out in the Kintampo
North and South districts of Ghana. The two districts
cover in total an area of 7162km2 and are located in the
forest-savannah transitional zones in the middle belt of
Ghana.ThetotalpopulationbasedontheHealthandDemo-
graphic Surveillance System (HDSS) of the Kintampo Health
Research Centre (KHRC) was approximately 126000 in the
2007 census (Kintampo Health Research Centre, annual
report, 2007) and the main economic base is subsistence
farming. The mean monthly temperature ranges from 18
◦C
to 38
◦C, and the average rainfall is 1250mm per annum,
creating optimal conditions for malaria transmission at
a rate of about 269 infective bites per person per year
[13].
2.2. Study Population. Adolescent and Adult patients
(age>14 years) seen at community-based clinics and
diagnosed as having uncomplicated malaria (fever+any
level of malaria parasitaemia) were eligible for enrolment
into this study. Patients who were unable to tolerate oral
therapy, not resident in the study area or unwilling to take
p a r ti nt h es t u d ya sw e l la sp r e g n a n tw o m e n ,w e r ee x c l u d e d
from the study.
2.3. Recruitment. Patients with signs and symptoms were
assessed and recorded by a study clinician. Participants who
satisﬁed the eligibility criteria (i.e., any signs and symptoms
ofmalaria+presenceofparasitaemia)wererecruitedintothe
study and randomised into one of two groups, supervised or
unsupervised groups.
2.4. Treatment. Artesunate and amodiaquine (IPCA Labo-
ratories, India) were prescribed according to body weight
(i.e.,bodyweight≥50Kg:100mgofartesunateand300mgof
amodiaquine; bodyweight <50Kg: 50mg of artesunate and
150mg of amodiaquine) and administered twice daily for
72 hours. All participants in each group received the ﬁrst
dose of antimalarial under observation and were educated
about AS+AQ dose regimen and the need for adherence as
per Ghana’s malaria treatment guidelines.
2.5. Randomization. Randomization was carried out in
blocks of twenty by tossing a coin to determine the ﬁrst
group. The ﬁrst block of twenty participants was allocated
into the supervised group. The subsequent block of twenty
participantswasallocatedintounsupervisedgroupandthese
were alternated until the desired sample size was achieved.
These large blocks were used to prevent overrepresentation
of patients coming from the same community allocated to
one group.
2.6. Follow-up. Participants in the supervised group were
visited at their homes by trained community workers
to administer subsequent treatment regimen under direct
observation on the second and third days of treatment,
and post-treatment days (third, seventh, 14, and 28). The
participants in the unsupervised group were advised to
self-administerthetreatmentandwerevisitedathomeonthe
third day for assessment of their adherence to the treatment
regimen, then on the seventh, 14th, and 28th posttreatment
days for parasite clearance and clinical resolution.
At each visit a symptom assessment questionnaire was
used to determine a patient’s clinical outcome. Participants
foundnottobeimprovingwerereferredtothehealthfacility,
reviewed further, and treated by the study clinician.
2.7. Laboratory Procedures. Venous blood samples (1mL)
were obtained prior to treatment to determine the haemato-
logical, biochemical, and malaria microscopy. Haemoglobin
levels were determined using ABX Micros 60 Haematology
Analyzer (Horiba ABX, France). Biochemical analyses were
determined using Selectra E Clinical Chemistry analyser
(Vital Scientiﬁc N.V., The Netherlands). Malaria parasite
density was estimated from malaria parasite counts per
200 white blood cells and then extrapolated to malaria
parasites per microlitre of blood with an assumption that a
microlitre of blood contains 8000 leucocytes. Two hundred
thick ﬁlm ﬁelds were examined before assigning a negative
malaria diagnosis. Prepared blood smears were read by
expert microscopy readers in Kintampo Health Research
Centre. Ten percent of positive and negative blood smears
were randomly selected and conﬁrmed by an independent
blinded microscopist.
2.8. Outcome Measures. The main outcome measure was
adherence to AS+AQ combination therapy. This was deﬁned
as the correct number of tablets of artesunate or amodi-
aquine left on the third day (day 2) of treatment when
the treatment regimen was expected to be completed. This
was assessed by direct observation of the blister package of
artesunate-amodiaquine tablets. Secondary outcome mea-
sures included parasite clearance rates on days 14 and 28
determined as the proportion of study participants in each
group without P. falciparum parasitaemia by microscopy and
clinical symptoms reported by day 7 determined as the pro-
portion of study participants in each group with symptoms
of malaria reported through a structured questionnaire by
day 7.Journal of Tropical Medicine 3
2.9. Sample Size. It was expected that about 65% of study
patients would adhere to medication under supervision and
about 50% would comply with the treatment without any
supervision. A sample size of 182 per arm was estimated
given 95% conﬁdence interval and a power of 80. Assuming
a 10% drop-out rate, about 202 participants were recruited
per group.
2.10. Data Analysis. Data were analysed using STATA 9
(StataCorp, College Station TX). Baseline characteristics and
the endpoints were compared between the two groups.
Point estimates were summarized as means and proportions
and interval estimates as ranges and 95% conﬁdence inter-
vals. Biochemical and hematological indices were described
according to the CTC AE v.3 grading classiﬁcation. All
statistical tests were two sided, and a P-value of ≤.05 was
considered indicative of a statistically signiﬁcant diﬀerence.
2.11. Ethical Issues. The study was approved by ethics com-
mittees of the Ghana Health Service. The study participants
were enrolled after obtaining informed written consent.
3. Results
3.1. Background Characteristics. A total of 520 participants
were screened for inclusion into the study. 211 and 190
participants were randomized into the supervised and
unsupervised groups, respectively (Figure 1).
The average age of the participants in the supervised and
unsupervised groups were 38.1 and 39.5 years, respectively,
and there was no statistically signiﬁcant diﬀerence in
the baseline characteristics between the two groups. The
mean weight among both groups was 49.6Kg (48.5–50.7)
(Table 1). The mean dosage/day of artesunate was similar
3.1 (95% CI 2.9–3.1) and 3.0 (95% CI 2.9–3.1)mg/Kg
body weight for the supervised and unsupervised groups,
respectively.Themeandosageforamodiaquinewas9.1(95%
CI 8.8–9.4) and 9.0 (95% CI 8.7–9.3)mg/Kg body weight for
the supervised and unsupervised groups, respectively.
3.2. Adherence to Artesunate-Amodiaquine Therapy. There
was no statistically signiﬁcant diﬀerence in adherence to
AS+AQ therapy between the supervised and unsupervised
groups (95.7% versus 92.6%; P = .18) There was no
association between sex, age, or education and adherence
to treatment regimen in the supervised and unsupervised
groups (Table 2).
There were no marked diﬀerences in the reported side
eﬀectswithintheﬁrstoneweekoftreatmentbetweenthetwo
groups (Table 3). Headache was the commonest side-eﬀect
reported within the ﬁrst week. The prevalence of headache
increased on Day 2 (supervised: 10.6%, unsupervised:
16.4%; P = .12) but decreased by Day 7 (supervised:
2.8%, unsupervised: 1.8%; P = .20). Body weakness, bodily
pains, joint pains, and drowsiness were the other commonly
reported side eﬀects after receiving treatment with AS-AQ.
Therewereuncontrollablebodymovementsamong10%and
5.9% of supervised and unsupervised participants, respec-
tively. These were mainly mild uncontrollable extension of
the neck and tongue. These cases resolved spontaneously
without hospitalization.
3.3. Haematological and Biochemical Side-Eﬀects. The pro-
portion of participants with anaemia (hb<11.0g/dL)
increased signiﬁcantly between day 0 and day 2 in both
groups. The proportion of anaemia among the supervised
group increased signiﬁcantly from 12.6% on day 0 to 38.8%
on day 2 (P<. 01). This pattern was similar in the
unsupervised group (15.8% on day 0 to 38.8% on day 2,
P ≤ .01). Majority of the participants haemoglobin levels
decreased by a margin between 0.9g/dL and 2g/dL from day
0t od a y2( s u p e r v i s e d= 79.4%, unsupervised = 81.5% P =
.64).
Total bilirubin, Aspartate Transaminase (AST), Alanine
Transaminase(ALT),Creatinine(Cr),andUrea(Ur)analyses
were carried out on day 0 and day 2 to assess liver and renal
functions. The proportion of high (≥grade 3 on CTC AE V3
classiﬁcation) biochemical indices were similar among both
groups on days 0 and 2 (Table 4).
The proportion of high creatinine levels were similar
a m o n gb o t hg r o u p so nd a y0( s u p e r v i s e d= 1.42%, unsu-
pervised=0.53%, P = .37) and day 2 (supervised=11.22%,
unsupervised=8.74%, P = .44). Though the proportion of
high(≥grade 3 on CTC AE V3 classiﬁcation) creatinine was
similar among the two groups at day 0 and 2, there was a
signiﬁcant increase by Day 2 compared with day 0 among
both supervised (P<. 0 1 )a n du n s u p e r v i s e d( P ≤ .01)
groups.
3.4. Parasite Clearance. There was no diﬀerence in the
proportion of participants who had parasites cleared on
day 28. As per protocol analysis, day 28 parasite clearance
was 98% (201/205) among those supervised, compared
with 99.5% (185/186) among those unsupervised. Day 28
parasiteclearancewas95.3%(201/211)and97.4%(185/190)
amongthesupervisedandunsupervisedgroups,respectively.
PCR was not carried out to distinguish recrudescence from
reinfections.
4. Discussion
In choosing a new drug or combination of drugs for
treatment of malaria, one has to consider several factors
such as therapeutic eﬃcacy, side eﬀects, patients’ perception
about the treatment regimen, cost, and availability and
accessibility of the drug(s) in question. While side eﬀects and
treatment regimen are key determinants to patient’s adher-
ence, perception of illness, treatment-seeking behaviour,
and acceptability and aﬀordability of the drug will also
inﬂuence adherence. Poor treatment practices may lead to
suboptimal blood levels or one of the drugs could be given
as monotherapy leading to population resistance as occurred
with chloroquine. Thus, periodic evaluation of adherence to
treatment regimen and optimum ways to ensure adherence
among target populations is important.4 Journal of Tropical Medicine
Day
0
Day
1
Day
2
Day
14
Day
28
Supervised = 211
Present = 211
Absent = 0
Present = 211
Absent = 0
Present = 208
Absent = 3
Present = 205
Absent = 6
Total screened = 520
Randomized = 401
Ineligible = 119
• No parasites
= 114
• Consent refusal = 1
• 1st trimester
pregnancy = 1
• Not resident in
study area = 3
Unsupervised = 190
Not visited
Present = 182
Absent = 8
Present = 187
Absent = 3
Present = 186
Absent = 4
Figure 1: Flow diagram of patient recruitment and follow up.
Adherencetothethree-daytreatmentregimenofAS+AQ
was very high in this study in both supervised and unsu-
pervised participants. In a feasibility study of the use of
artemether-lumefantrine which has a more complicated
three day treatment regimen, >80% of care-givers in south-
ern Ghana correctly administered the drug [14]. A similar
study in southern Ghana and other African countries using
AS+AQ also demonstrated a high rate of adherence (81%–
97%) among caregivers [15]. These result suggests that
high levels of adherence to AS+AQ can be achieved in
rural communities if an eﬀective education programme
on treatment regimen is in place. However, the adherence
rates observed in this study may be an overestimation;
though the study tried to mimic the routine programme
situation in the unsupervised group, the consenting process
and home visits by study staﬀ which are not part of the
normal practices in the routine malaria case management
heath care delivery system could have promoted adherence
to therapy beyond what will normally be expected. As part
of Ghana’s treatment guidelines for uncomplicated malaria
with AS+AQ, a prescribing clinician is obliged to explain the
treatment regime and possible side-eﬀects to his/her client.
This practice was strictly followed in the study and may
have inﬂuenced the high adherence rates observed. In the
training of prescribing clinicians, pharmacist, and chemical
sellers, patient education on drug regimen and possible
side-eﬀects should be emphasized to ensure adherence. This
will particularly be crucial if AS+AQ should in future
be deployed for home treatment of malaria as part of
the Integrated Management of Childhood Illnesses (IMCI)
programme.
Adherence to treatment is likely to be aﬀected by factors
such as age, number of tablets and duration of treatment.
In the case of AS+AQ adult patients are expected to take
between 12 and 24 tablets of AS+AQ tablets over three days.
The introduction of the ﬁxed dose of AS+AQ has halved the
number of tablets and this is likely to enhance adherence
[16]. However, a study designed to evaluate adherence to
the ﬁxed dose of AS+AQ under unsupervised conditions is
needed.
Theside-eﬀectsreportedin thisstudyaresimilartothose
reported in controlled studies [17] with the commonest
being headache. Majority of side-eﬀects had resolved within
one (1) week of treatment. Body weakness was commonly
reported within the ﬁrst two days posttreatment. Generally,
the reported symptoms among this cohort of adults areJournal of Tropical Medicine 5
Table 1: Age, sex, and educational characteristics of study participants.
Supervised % (n) Unsupervised % (n)
Number of respondents 211 190
Mean age, years (95% CI) 38.1 (37.7–40.4), 39.5 (37.1–41.9)
Sex
Males 34.6 (73) 36.8 (70)
Females 65.4 (138) 63.2 (120)
Educational background
None 44.5 (94) 53.7 (102)
Primary 20.9 (44) 16.8 (32)
Middle school, JSS 29.4 (62) 27.4 (52)
Technical/commercial/SSS/post Sec 5.2 (11) 2.1 (4)
Physical Examination
Mean weight, Kg (95% CI) 49.6 (48.5–50.7) 49.7 (48.7–50.7)
Mean temperature (95% CI) 37.9 (37.8–38.0) 38.0 (37.9–38.0)
Biochemical
Proportion with sexual parasite (%) 2.4 (5/211) 3.2 (6/190)
Mean hemoglobin, g/dL (95% CI) 12.4 (12.1–12.6) 12.4 (11.4–13.3)
Geometric mean ALT, U/L (95% CI) 9.0 (7.9, 10.2) 8.7 (7.6, 10.1)
Geometric mean AST, U/L (95% CI) 35.0 (32.9, 37.1) 35.9 (33.6, 38.3)
Geometric mean TBil, µmol/L (95% CI) 12.2 (11.1, 13.5) 11.6 (10.3, 13.1)
Geometric mean Ure, mmol/L (95% CI) 3.1 (2.9, 3.3) 2.8 (2.6, 3.0)
Geometric mean Cre, µmol/L ( 95% CI) 68.8 (66.2, 71.5) 67.7 (65.4, 70.1)
ALT:Alanine transaminase, AST:Aspartate transaminase, TBil:Total transaminase, Ure:Urea, Cre=Creatinine, 95% CI:95% Conﬁdence Interval.
Table 2: Predictors of adherence to artesunate-amodiaqiune treat-
ment.
Factor Odds ratio (95% CI) P-value∗
Group
Unsupervised 1.00
Supervised 1.82 (0.76, 4.33) .18
Sex
Women 1.00
Men 0.93 (0.38 2.26) .87
Age group
age-groups > 20 1.00
age-groups ≤ 20 1.25 (0.34, 4.57) .76
Education
Education 1.00
No Educated 1.36 (0.55,3.56) .51
less than that reported among children who were treated
with AS+AQ in northern Ghana [18]. Compliance among
participants in both supervised and unsupervised groups
was high irrespective of side-eﬀects they experienced during
treatment phase. This is consistent with the perception of
healing in rural areas ,that is, a period of worsening illness
followed by a period of wellbeing.
Supervision of home treatment of malaria by health
workers was perceived to be acceptable among participants
in the supervised group. They were willing to allow health
workers within their communities to supervise their drug
administration.Inareaswherecommunity-basedhealthpro-
gramme services (CHPSs) are available, public health nurses
could supervise malaria treatment, observe the progress of
the sick child, and refer where appropriate. This process will
increase parasite clearance and prevent resistance as has been
reported among children in Gabon [19].
There was a signiﬁcant increase in the proportion of
anaemia among the study participants. A decrease in
haemoglobin levels was observed on day 2 following treat-
ment; this was similar to the pattern of haemoglobin
dynamics among younger children treated with artemisinin
combination drugs (including AS+AQ) in the same area.
In these children, there was an initial drop in haemoglobin
followed by an increase by day 14 [20]. A similar pattern
of haematological recovery post malaria treatment has been
reported among other children in northern Ghana [18]
and Kenyan children [21]. In this study, haemoglobin levels
were determined only on days 0 and 2. Haemoglobin levels
are likely to have increased by day 14 as was found in
younger children. Further studies are required to understand
haematological recovery processes following treatment with
artemisinins in adults.
The eﬃcacy of AS+AQ in adult study group in this
high malaria transmission area is comparable to AS+AQ
eﬃcacy results in other studies where malaria transmission
is similarly high: 98.6% obtained in northern Ghana [22],
92.7% in Senegal [23], and 100% in Uganda [24].
Inconclusion,bothsupervisedandunsupervisedadmin-
istration of AS+AQ resulted in high levels of adherence to
treatment regimen among an adult population in a rural6 Journal of Tropical Medicine
Table 3: Reported side-eﬀects within 7 day post ﬁrst dose.
Symptom Day 1∗ Day 2 Day 3 Day 7
Sup. Sup. Unsup. P-value Sup. Unsup. P-value Sup. Unsup. P-value
(%) (%) (%) (%) (%) (%)
Headache 11.2 — 10.6 16.4 .12 7.3 11.5 .44 2.8 1.8 .56
Body weakness 15.5 — 13.6 7.9 .20 0.0 0.0 — 0.9 1.1 .87
Bodily pain 8.0 — 9.9 6.5 .22 5.7 8.8 .48 2.5 3.3 .64
Joint pain 6.6 — 8.0 10.4 .43 4.9 10.8 .22 4.0 1.7 .17
Drowsiness 5.1 — 4.2 7.8 .26 0.0 3.3 — 0.0 0.0 —
Uncontrollable body mov’t 2.0 — 10.3 5.9 .11 5.4 5.7 .94 2.0 2.2 .89
Nausea 1.0 — 2.9 3.0 .92 4.4 2.7 .57 1.5 3.6 .17
Abdominal pain 2.4 — 3.3 2.1 .46 1.3 1.4 .98 1.9 3.7 .27
Itching 1.4 — 0.0 2.0 — 1.3 0.0 .32 1.9 2.6 .63
Diﬃculty in sleeping 1.4 — 3.3 1.0 <. 01 2.7 1.4 .57 3.3 6.3 .15
Lost of appetite 0.9 — 3.7 3.1 .72 6.6 3.9 .46 3.7 2.6 .51
Diarrhoea 0.0 — 2.3 1.0 .32 0.0 1.4 — 1.8 3.1 .40
Palpitation 0.9 — 1.4 0.5 .38 0.0 0.0 — 0.9 1.0 .89
Rash 0.5 — 0.0 0.0 — 0.0 0.0 — 0.5 0.5 .93
Vomiting 0.0 — 0.5 0.5 .94 0.0 0.0 — 0.0 0.0 —
∗Unsupervised group were not assessed on day 1, Sup:supervised group; Unsup:Unsupervised group; Ave:average of supervised and unsupervised groups.
Table 4: Proportion of participants with high (≥grade 3 CTCAE v3 classiﬁcation) haematological and biochemical indices at Days 0 and 2.
Biochemical assessment Day 0 Day 2
Supervised Unsupervised P-value Supervised Unsupervised P-value
n(%) n(%) n(%) n(%)
Hemoglobin 1 (0.47) 3 (1.58) .26 3 (1.42) 5 (2.63) .07
Alanine transaminase 1 (0.54) 1 (0.60) .94 1 (0.54) 1 (0.60) .94
Aspartate transaminase 1 (0.48) 2 (1.06) .50 0 (0.00) 3 (1.96) —
Total bilirubin 4 (1.96) 3 (1.62) .25 4 (2.06) 7 (4.02) .27
Urea 1 (0.48) 1 (0.53) .94 7 (3.72) 4 (2.34) .45
Creatinine 3 (1.42) 1 (0.53) .37 23 (11.22) 16 (8.74) .44
Note: The proportion of high creatinine was similar among the two groups at days 0 and 2; there was a signiﬁcant increase by Day 2 compared with day 0
among both supervised (P<. 01) and unsupervised (P ≤ .01) groups.
district in Ghana. Although this may have been inﬂuenced
by the intensity of research related activities, it nevertheless
gives a good indication of the potential to achieve high
level patient adherence through rigorous routine patient
education.
Limitations. Adherence to therapy was assessed using the
number of tablets left in the sachets which is dependent
on what participants showed to the investigators. A better
method could have been an estimation of drug levels in
blood or urine. However, this test is expensive. In the
absence of such estimates, the observation method was
used. In communities were participants in both groups
existed concurrently, adherence levels could have been
inﬂuenced by contamination. However, this is unlikely
due to the short duration between drug treatment and
adherence assessment during which sick adolescents and
adults are unlikely to move around to cause contamina-
tion. Additionally, randomisation was done in blocks of
20 to minimise contamination during the short treatment
duration.
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